- In early July 2026, Revolution Medicines reported Phase 1/2 data showing that its investigational RAS(ON) G12D inhibitor zoldonrasib, alone and in combinations, delivered high response and disease control rates with manageable safety in patients with metastatic pancreatic ductal adenocarcinoma.
- Because there are currently no approved targeted therapies for RAS G12D cancers, these early results position zoldonrasib-based regimens as potentially important additions to treatment options if larger Phase 3 trials are successful.
- We’ll now examine how these early zoldonrasib combination results in metastatic pancreatic cancer could influence Revolution Medicines’ broader RAS(ON) investment narrative.
The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.
Revolution Medicines Investment Narrative Recap
To own Revolution Medicines, you need to believe that its RAS(ON) pipeline can turn strong early pancreatic data into approved therapies across multiple tumor types before cash burn and trial risk catch up. The zoldonrasib combination results directly reinforce the near term clinical catalyst in first line metastatic pancreatic cancer, while also sharpening the key risk that any disappointing Phase 3 readout across this concentrated program could quickly reset expectations.
Among recent announcements, the start of the RASolute 305 Phase 3 trial in first line RAS G12D metastatic pancreatic cancer looks most relevant. The new zoldonrasib data feed directly into that study’s rationale by showing combination activity and tolerability in both chemotherapy and daraxonrasib pairings, so many investors are now watching how these early signals might translate into eventual RASolute 305 outcomes and the broader registrational program.
Yet despite these promising data, investors should still be aware that...
Read the full narrative on Revolution Medicines (it's free!)
Revolution Medicines' narrative projects $1.0 billion revenue and $148.6 million earnings by 2029. This implies an earnings increase of about $1.3 billion from -$1.1 billion today.
Uncover how Revolution Medicines' forecasts yield a $133.70 fair value, a 27% downside to its current price.
Exploring Other Perspectives
Some of the lowest analysts were expecting only about US$839,000,000 of revenue and US$159,000,000 of earnings by 2029, so if you are weighing today’s zoldonrasib news against those cautious forecasts, it is worth remembering that informed views on Revolution Medicines can differ widely and may shift as more pancreatic data emerge.
Explore 5 other fair value estimates on Revolution Medicines - why the stock might be worth 27% less than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Revolution Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Revolution Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revolution Medicines' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Find 46 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com